Abstract
Implementation of a public vaccination program with A/New Jersey (A/NJ) vaccines in 1976 led to the recognition of an increased risk among vaccinated persons of developing the neurological disorder known as Guillain–Barré Syndrome (GBS). The attributable risk was 8.8 among adults in the 6-week period after vaccination or about 1 case per 100,000 vaccinations. Skepticism of the statistically significant association was resolved with a subsequent careful assessment in two states in the USA that confirmed the association. Subsequent efforts to confirm an association between other influenza vaccines and occurrence of GBS have mostly failed to identify an association but a suggestion of about one case of GBS per one million vaccinations has been reported. GBS has been associated with various other infections, illnesses, vaccinations, and other disorders. Campylobacter jejuni infections are accepted as inducing a risk for GBS and evidence suggests antiganglioside immune responses that react with the nerve myelin sheath as the mechanism. To assess this possibility, A/NJ and some other influenza vaccines were all shown to induce antiganglioside antibodies in mice; however, a relation of this finding in mice to GBS in humans has not been provided.
More recently, reports have indicated a risk of GBS after clinical influenza that is greater than the risk after influenza vaccination, suggesting that influenza vaccination may actually protect against GBS. Influenza, influenza vaccinations, and their role in the occurrences of GBS are evolving subjects. At present, however, occurrence of GBS cannot be considered an inherent risk of influenza vaccination.
Keywords
- Influenza Vaccine
- Influenza Vaccination
- Influenza Infection
- Swine Influenza
- Vaccine Adverse Event Reporting System
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Sencer DJ, Millar JD (2006) Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis 12:29–33
Schonberger LB, Bregman DJ, Sullivan-Bolyal JZ, Keenlyside RA, Ziegler DW, Retailliau HF, Eddins DL, Bryan JA (1979) Guillain–Barre syndrome following vaccination in the National Influenza Immunization Program. United States, 1976-1977. Am J Epidemiol 110:105–122
Johnson DE (1982) Guillain-Barre syndrome in the US Army. Arch Neurol 39:21–24
Beghi E, Kurland LT, Mulder DW, Wiederholt WC (1985) Guillain-Barre syndrome: clinicoepidemiologic features and effect of influenza vaccine. Arch Neurol 42:1053–1057
Kurland LT, Wiederholt WC, Kirkpatrick JW, Potter HG, Armstrong P (1985) Swine influenza vaccine and Guillain-Barre syndrome. Epidemic or Artifact? Arch Neurol 42:1089–1092
Marks JS, Halpin TJ (1980) Guillain-Barre syndrome in recipients of A/New Jersey influenza vaccine. JAMA 243:2490–2494
Breman JG, Hayner NS (1984) Guillain-Barre syndrome and its relationship to swine influenza vaccination in Michigan, 1976-1977. Am J Epidemiol 119:880–889
Safranek TJ, Lawrence DN, Kurland LT, Culver DH, Wiederholt WC, Hayner NS, Osterholm MT, O’Brien P, Hughes JM, Expert Neurology Group (1991) Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: Results of a two-state study. Am J Epidemiol 133:940–951
Asbury AK, Arnason BG, Karp HR, McFarlin DE (1978) Criteria for diagnosis of Guillain-Barre syndrome. Ann Neurol 3:565–566
Asbury AK, Cornblath DR (2004) Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 27:S21–S24
Sejvar J, Cornblath D, Hughes R, The Brighton Collaboration Guillain-Barre Syndrome Working Group. (2008) The Brighton Collaboration case definition for Guillain-Barre syndrome as an adverse event following immunization. Inflammatory Neuropathy Consortium Meeting, Paris, France, July 2008
Kennedy RH, Danielson MA, Mulder DW, Kurland LT (1978) Guillain-Barre Syndrome. A 42-year epidemiologic and clinical study. Mayo Clin Proc 53:93–99
van Doorn PA, Ruts L, Jacobs BC (2008) Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 7:939–950
Leneman F (1966) The Guillain-Barre syndrome. Arch Intern Med 118:139–144
Melnick SC, Flewett TH (1964) Role of infection in the Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 27:385–407
Langmuir AD (1979) Guillain-Barre syndrome: the swine influenza virus vaccine incident in the United States of America, 1976-77: preliminary communication. J R Soc Med 72:660–669
Schonberger LB, Hurwitz ES, Katona P, Holman RC, Bregman DJ (1981) Guillain-Barre syndrome: its epidemiology and associations with influenza vaccination. Ann Neurol 9:31–38
Black S, Eskola J, Siegrist C-A, Halsey N, MacDonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D et al (2009) Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet 374(9707):2115–2122
Sliman NA (1978) Outbreak of Guillain-Barre syndrome associated with water pollution. Br Med J 1:751–752
Haymaker W, Kernohan JW (1949) The Landry-Guillain-Barre syndrome: a clinical pathologic report of 50 fatal cases and a review of the literature. Medicine 28:59–141
Zhu J, Mix E, Link H (1998) Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barre syndrome. J Neuroimmunol 84:40–52
Ariga T, Miyatake T, Yu RK (2001) Recent studies on the roles of antiglycosphingolipids in the pathogenesis of neurological disorders. J Neurosci Res 65:363–370
McCarthy N, Giesecke J (2001) Incidence of Guillain-Barre syndrome following infection with Campylobacter jejuni. Am J Epidemiol 153:610–614
Yuki N (2001) Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis 1:29–37
Rees JH, Soudain SE, Gregson NA, Hughes RAC (1995) Campylobacter jejuni infection and Guillain-Barre syndrome. BMJ 333:1374–1379
Bereswill S, Kist M (2003) Recent developments in Campylobacter pathogenesis. Curr Opin Infect Dis 16:487–491
Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H, Corcoran AT, Iskander JK, Schonberger LB, Chen RT (2008) Anti-ganglioside antibody induction by swine (A/NJ/19976/H1N1) and other influenza vaccines: Insights into vaccine-associated Guillain-Barre syndrome. J Infect Dis 198:226–233
Hurwitz ES, Schonberger LB, Nelson DB, Holman RC (1981) Guillain-Barre syndrome and the 1978-1979 influenza vaccine. New Engl J Med 304:1557–1561
Kaplan JE, Katona P, Hurwitz ES, Schonberger LB (1982) Guillain-Barre syndrome in the United States, 1979-1980 and 1980-1981. JAMA 248:698–700
Kaplan JE, Schonberger LB, Hurwitz ES, Katona P (1983) Guillain-Barre syndrome in the United States, 1978-1981: Additional observations from the national surveillance system. Neurology 33:633–637
Lasky T, Terracciano GJ, Magder I, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, Schonberger LB et al (1998) The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. New Engl J Med 339:1797–1802
Stowe J, Andrews N, Wise L, Miller E (2009) Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom general practice research database. Am J Epidemiol 169:382–388
Roscelli JD, Bass JW, Pang L (1991) Guillain-Barre syndrome and influenza vaccination in the US Army, 1980-1988. Am J Epidemiol 133:952–955
Centers for Disease Control and Prevention (2003) Surveillance Summaries, January 24, 2003. Surveillance for Safety after immunization: vaccine adverse event reporting system (VAERS) – United States, 1991–2001. MMWR 52 (No. SS-1)
Geier MR, Geier DA, Zahalsky AC (2003) Influenza vaccination and Guillain Barre syndrome. Clin Immunol 107:116–121
Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT (2004) Guillain-Barre syndrome following influenza vaccination. JAMA 292:2478–2481
Souayah N, Nasar A, Fareed M, Suri K, Qureshi AI (2007) Guillain-Barre syndrome after vaccination in United States. A report from the CDC/FDA vaccine adverse event reporting system. Vaccine 25:5253–5255
Juurlink DN, Stukel TA, Kwong J, Kopp A, McGeer A, Upshur RE, Manuel DG, Moineddin R, Wilson K (2006) Guillain-Barre syndrome after influenza vaccination in adults. Arch Intern Med 166:2217–2221
Haber P, Slade B, Iskander J (2007) Letter to the editor. Vaccine 25:8101
Tam CC, O’Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC (2007) Guillain-Barre syndrome and preceding infection with Campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS ONE 2(4):e344. doi:10.1371/journal.pone.0000344
Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand M-C, Enouf V, Rozenberg F, Caudie C, Annane D, van der Wert S et al (2009) Guillain-Barre syndrome and influenza virus infection. Clin Infect Dis 48:48–56
Acknowledgments
Financial support: Research performed by the authors and summarized in this report was supported by Public Health Service Contract NO1-AI-30039 from the National Institute of Allergy and Infectious Diseases.
The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Birkhäuser Basel
About this chapter
Cite this chapter
Couch, R.B. (2011). Occurrences of the Guillain–Barré Syndrome (GBS) After Vaccinations with the 1976 Swine A/H1N1 Vaccine, and Evolution of the Concern for an Influenza Vaccine-GBS Association. In: Rappuoli, R., Del Giudice, G. (eds) Influenza Vaccines for the Future. Birkhäuser Advances in Infectious Diseases. Springer, Basel. https://doi.org/10.1007/978-3-0346-0279-2_16
Download citation
DOI: https://doi.org/10.1007/978-3-0346-0279-2_16
Published:
Publisher Name: Springer, Basel
Print ISBN: 978-3-0346-0278-5
Online ISBN: 978-3-0346-0279-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)